Diabetes
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global diabetes market insights. Get critical pharma intelligence on R&D, regulatory approvals, and investment opportunities for diabetes treatments.
Showing 1–12 of 29 articles
Quick answer
NovaPharmaNews Diabetes hub for FDA covers 29 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
GLP-1 usage statistics show broad uptake and mixed clinical signals
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications
Spotlight On: Four Things to Watch at ADA 2026
FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
Tracking Cellular Disruptions in Type 1 Diabetes: Insights for Pharma
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
COFEPRIS Drug Approvals 2026: What You Need to Know
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.